The cases of pediatric medulloblastoma are rapidly increasing and accounts about two people per million per year worldwide. The treatment options for medulloblastoma are maximal safe resection (plus/minus CSF diversion), neuraxis radiotherapy and chemotherapy. Recent advances in cancer biology have changed the emphasis onto novel agents that target molecular changes crucial for tumour proliferation or survival.